Sotatercept is a drug approved for pulmonary arterial hypertension (PAH) that improves mortality, right ventricular function, functional class, NT-proBNP, and 6-minute walk distance. However, no clinical trials support its use in patients with pulmonary hypertension (PH) and interstitial lung disease (ILD), and respira...
Fernando Vargas-Ursúa, Alejandro Cruz-Utrilla, Andrés Tenes· Open Respiratory Archives· 0 citations
Pulmonary hypertension (PH) is frequent and impactful in respiratory disease, but its characteristics in the Spanish population are unknown. We aimed to describe the clinical features and outcomes of patients with PH associated with COPD, interstitial lung disease (ILD) and combined pulmonary fibrosis and emphysema...
L. Piccari, Manuel López-Meseguer, Á. Cantero-Acedo et al.· ERJ Open Research· 0 citations
Portopulmonary hypertension (PoPH) is a complex and underrecognized form of pulmonary arterial hypertension arising in the setting of portal hypertension, in which outcomes are driven by the interplay between pulmonary vascular disease and liver dysfunction. Despite advances in hemodynamic definitions and targeted ther...
J. Donate, S. del Prado, Andrés Tenes et al.· Annals of Hepatology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
